phrykt

Acumen Pharmaceuticals, Inc. (ABOS): who owns it and who trades it

As of Nov 16, 2026, ABOS insiders reported 42 open-market sales worth $592K and no purchases in the last 12 months, with 15% of the sale value made under pre-set 10b5-1 plans. The largest seller was Derek M Meisner (Chief Legal Officer & Co), with $238K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Acumen Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ABOS

97 funds and institutions reported ABOS shares worth $128M at the end of Q2 2026, about 66% of the company. The largest holder is Ra Capital Management, L.P. with 29.1%.

Funds and institutions (13F) 66%Everyone else 34%

10 largest owners, by share of the company

Ra Capital Management, L.P.29.1%
Sands Capital Alternatives, LLC5.2%
BlackRock, Inc.3.4%
Alyeska Investment Group, L.P.3.4%
Franklin Resources Inc3.2%
ADAR1 Capital Management, LLC2.9%
Vanguard Capital Management LLC2.3%
Knollwood Investment Advisory, LLC2.3%
Geode Capital Management, LLC1.6%
Ikarian Capital, LLC1.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.20.99M29.07%$56.1MNo change
Sands Capital Alternatives, LLC3.72M5.15%$9.9MNo change
BlackRock, Inc.2.49M3.45%$6.6M+1296%
Alyeska Investment Group, L.P.2.45M3.40%$6.6MNo change
Franklin Resources Inc2.31M3.19%$6.2MNo change
ADAR1 Capital Management, LLC2.11M2.92%$5.6M-2%
Vanguard Capital Management LLC1.67M2.32%$4.5M+11%
Knollwood Investment Advisory, LLC1.63M2.26%$4.3MNo change
Geode Capital Management, LLC1.14M1.58%$3M+174%
Ikarian Capital, LLC1.05M1.46%$2.8MNo change
Hudson Bay Capital Management LP955,0001.32%$2.5M-1%
Pathstone Holdings, LLC859,1101.19%$2.3MNo change
Renaissance Technologies LLC675,0250.93%$1.8M+42%
Two Sigma Investments, LP622,8820.86%$1.7M+17%
State Street Corp600,5280.83%$1.6M+296%
Northern Trust Corp360,7440.50%$963K+380%
Vanguard Portfolio Management LLC320,7950.44%$857KNew
Dimensional Fund Advisors LP291,5590.40%$779K+143%
Vanguard Fiduciary Trust Co291,2400.40%$778K+46%
Bank of America Corp274,7810.38%$734K-14%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ABOS insiders reported $0 of open-market purchases and $592K of sales. 15% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$592K
42 trades, 9 people
Sales under a 10b5-1 plan
15%
Share of sale value
Latest trade
Jun 17, 2026
Filed Jun 17, 2026

Purchases and sales by month

$467K$467KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 17, 2026Derrell PorterDirectorSale13,040$2.33$30.4KForm 4
Jun 16, 2026Derrell PorterDirectorSale12,800$2.33$29.8KForm 4
Jun 15, 2026Derrell PorterDirectorSale6,460$2.35$15.2KForm 4
Jun 9, 2026Nathan B FountainDirectorSale6,400$2.23$14.3KForm 4
Mar 6, 2026Derek M MeisnerChief Legal Officer & CoSale plan2,090$3.26$6.8KForm 4
Feb 27, 2026Derek M MeisnerChief Legal Officer & CoSale plan9,406$3.01$28.3KForm 4
Jan 28, 2026Derek M MeisnerChief Legal Officer & CoSale plan2,671$3.00$8KForm 4
Jan 26, 2026Derek M MeisnerChief Legal Officer & CoSale plan15,085$3.00$45.3KForm 4
Jan 23, 2026Derek M MeisnerChief Legal Officer & CoSale5,633$1.90$10.7KForm 4
Jan 22, 2026Derek M MeisnerChief Legal Officer & CoSale1,054$1.84$1.9KForm 4
Jan 22, 2026Eric SiemersChief Medical OfficerSale895$1.82$1.6KForm 4
Jan 22, 2026Matt ZugaCFOSale1,687$1.86$3.1KForm 4
Jan 22, 2026Daniel Joseph OConnellCEOSale2,689$1.88$5.1KForm 4
Jan 22, 2026Russell BartonChief Operating OfficerSale462$1.84$850Form 4
Jan 21, 2026Derek M MeisnerChief Legal Officer & CoSale2,247$1.81$4.1KForm 4
Jan 21, 2026Eric SiemersChief Medical OfficerSale2,331$1.80$4.2KForm 4
Jan 21, 2026Matt ZugaCFOSale2,473$1.81$4.5KForm 4
Jan 21, 2026Daniel Joseph OConnellCEOSale9,346$1.81$16.9KForm 4
Jan 21, 2026Russell BartonChief Operating OfficerSale2,315$1.81$4.2KForm 4
Jan 12, 2026Derek M MeisnerChief Legal Officer & CoSale8,548$1.71$14.6KForm 4
Jan 12, 2026Daniel Joseph OConnellCEOSale5,388$1.73$9.3KForm 4
Jan 9, 2026Derek M MeisnerChief Legal Officer & CoSale5,200$1.76$9.2KForm 4
Jan 9, 2026Daniel Joseph OConnellCEOSale12,941$1.76$22.8KForm 4
Jan 8, 2026Matt ZugaCFOSale6,888$1.82$12.5KForm 4
Jan 8, 2026Russell BartonChief Operating OfficerSale3,530$1.86$6.6KForm 4
Jan 8, 2026Derek M MeisnerChief Legal Officer & CoSale30,092$1.82$54.8KForm 4
Jan 8, 2026Derek M MeisnerChief Legal Officer & CoSale6,819$1.82$12.4KForm 4
Jan 8, 2026Daniel Joseph OConnellCEOSale8,143$1.82$14.8KForm 4
Jan 8, 2026James J. DohertyPresidentSale6,467$1.82$11.8KForm 4
Jan 7, 2026James J. DohertyPresidentSale1,700$1.99$3.4KForm 4
Jan 7, 2026Amy SchacterleChief Regulatory OfficerSale1,097$1.98$2.2KForm 4
Jan 7, 2026Matt ZugaCFOSale4,105$2.00$8.2KForm 4
Jan 7, 2026Daniel Joseph OConnellCEOSale37,755$1.99$75.1KForm 4
Jan 7, 2026Derek M MeisnerChief Legal Officer & CoSale10,070$1.99$20KForm 4
Jan 6, 2026Matt ZugaCFOSale5,100$1.97$10KForm 4
Jan 6, 2026Eric SiemersChief Medical OfficerSale6,834$1.97$13.5KForm 4
Jan 6, 2026Daniel Joseph OConnellCEOSale5,102$1.97$10.1KForm 4
Jan 6, 2026Derek M MeisnerChief Legal Officer & CoSale7,097$1.97$14KForm 4
Jan 6, 2026Derek M MeisnerChief Legal Officer & CoSale3,801$1.97$7.5KForm 4
Jan 6, 2026Russell BartonChief Operating OfficerSale3,618$1.97$7.1KForm 4
Jan 5, 2026Matt ZugaCFOSale4,000$1.96$7.8KForm 4
Jan 5, 2026Daniel Joseph OConnellCEOSale4,649$1.97$9.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Derek M MeisnerChief Legal Officer & Corp Sec–$238KMar 6, 2026
Daniel Joseph OConnellChief Executive Officer, Director–$163KJan 22, 2026
Derrell PorterDirector–$75.4KJun 17, 2026
Matt ZugaCFO & Chief Business Officer–$46.2KJan 22, 2026
Eric SiemersChief Medical Officer–$19.3KJan 22, 2026
Russell BartonChief Operating Officer–$18.7KJan 22, 2026
James J. DohertyPresident and CDO–$15.2KJan 8, 2026
Nathan B FountainDirector–$14.3KJun 9, 2026
Amy SchacterleChief Regulatory Officer–$2.2KJan 7, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ABOS short interest

Moderate short interest. 6.3% of ABOS shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 161%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.56M ABOS shares were sold short, 6.3% of the shares outstanding, up 47.4% from the report before. At the average daily volume of 6.86M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

6.30%May 15Oct 306.88%

Days to cover

1.0May 15Oct 3011.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.56M6.30%+47%6.86M1.0
Oct 15, 20263.09M4.27%+0%569,5715.4
Sep 30, 20263.08M4.26%+10%641,5184.8
Sep 15, 20262.80M3.88%-11%343,8298.2
Aug 31, 20263.16M4.37%-2%384,0068.2
Aug 14, 20263.23M4.46%-4%310,00110.4
Jul 31, 20263.37M4.66%+20%355,7819.5
Jul 15, 20262.81M3.90%+1%374,8757.5
Jun 30, 20262.79M3.86%+48%1.07M2.6
Jun 15, 20261.89M2.61%-0%321,4195.9
May 29, 20261.89M2.62%+8%344,8195.5
May 15, 20261.75M2.42%+4%273,4876.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Acumen Pharmaceuticals company events

Acumen Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (job cuts). The latest was on Nov 5, 2026.

  1. Nov 5, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  2. Oct 30, 2026AnnouncementOf this Current Report on Form 8-K (this “Report”). Filing
  3. Oct 26, 2026ResultsReleased financial results. Filing
  4. Sep 16, 2026AnnouncementShared information with investors. Filing
  5. Aug 12, 2026ResultsReleased financial results. Filing
  6. Jun 16, 2026AnnouncementThe Company announced the nomination of two EBD development candidates for the treatment of AD pursuant to its collaboration agreement with JCR and the exercise of its option pursuant to the collaboration agreement to license and develop such development candidates. Filing
  7. Jun 3, 2026VoteReported shareholder vote results. Filing
  8. May 12, 2026ResultsReleased financial results. Filing
  9. Mar 26, 2026ResultsReleased financial results. Filing
  10. Mar 16, 2026AgreementAcumen Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement, 10,833,331… Filing
  11. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Acumen Pharmaceuticals financials

Famous investors that hold ABOS

2 of the 50 well-known investors we track reported holding ABOS in their latest 13F filing. The largest position is Jim Simons's, worth $1.4M.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026614,654$1.4M0.0%-9%
Ken Griffin · Citadel AdvisorsQ3 202637,990$84.3K0.0%-26%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Acumen Pharmaceuticals, Inc. (ABOS) stock

Who owns the most ABOS stock?

The largest reported owner of Acumen Pharmaceuticals, Inc. (ABOS) is Ra Capital Management, L.P., with 29.1% of the company. In total, 97 funds and institutions reported holding ABOS at the end of Q2 2026, together about 66% of the shares. See the largest owners.

Are ABOS insiders buying or selling?

In the last 12 months, ABOS insiders reported no open-market purchases and 42 sales worth $592K. The latest trade was on Jun 17, 2026. See every trade.

What is the short interest in ABOS?

As of Oct 30, 2026, 4.56M ABOS shares were sold short, 6.3% of the shares outstanding, up 47.4% from the report before. At the average daily volume of 6.86M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold ABOS?

2 of the 50 well-known investors we track reported ABOS in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $1.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.